½ÃÀ庸°í¼­
»óǰÄÚµå
1654282

¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¼÷ÁÖ ¼¼Æ÷º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Research-grade Proteins Market Size, Share & Trends Analysis Report By Product, By Host Cell, By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ »õ·Î¿î º¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 17¾ï 5õ¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö 11.49%ÀÇ ¿¬Æò±Õ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Ï ¿¬±¸ ºÐ¾ßÀÇ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ ÀÓ»ó ¿¬±¸¸¦ À§ÇØ ¿©·¯ ±¹°¡¿¡¼­ Á¤ºÎ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÁÖµµ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °³¹ß µµ»ó±¹ÀÇ »ý¸í °øÇÐ »ê¾÷ÀÇ ¹ßÀüÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÁÖµµÇϰí ÀÖ½À´Ï´Ù..

COVID-19 ´ëÀ¯ÇàÀº ¹é½Å, Áø´Ü ¹× Ä¡·áÁ¦ °³¹ßÀ»À§ÇÑ ¿¬±¸ Ȱµ¿ÀÌ ±ÞÁõÇÏ¿© ½ÃÀå¿¡ ±àÁ¤Àû ÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÌ ¹é½Å Èĺ¸¹°ÁúÀÇ ½ÂÀÎ ÀýÂ÷¸¦ ½Å¼ÓÈ÷ ó¸®ÇÏ´Â µ¥ ÁÖ·ÂÇϸ鼭 À§Å¹ Á¦Á¶¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù. mRNA ¹é½Å°ú °°Àº »õ·Î¿î ¹é½Å Ç÷§ÆûÀÌ Å« ÁÖ¸ñÀ» ¹Þ¾ÒÁö¸¸, ¿©·¯ ÀçÁ¶ÇÕ ´Ü¹éÁú ¹é½Å ´ë¾Èµµ Æò°¡µÇ°í ÀÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù Novavax, Inc.ÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú ±â¹Ý COVID-19 ¹é½ÅÀÎ Nuvaxovid(NVX-CoV2373)´Â EU¿¡¼­ Á¶°ÇºÎ ½ÃÆÇ Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ ÆÒµ¥¹ÍÀº »ý¹°ÇÐÀû Á¦Á¦ ºÐ¾ß¿¡¼­ ¹ÎøÇϰí À¯¿¬ÇÑ Á¦Á¶ ´É·ÂÀÇ Çʿ伺À» °­Á¶Çß½À´Ï´Ù. ÀÌ ¿äÀÎÀº °¡±î¿î ¹Ì·¡¿¡ °æÀï ȯ°æÀ» °­È­ÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁø ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2019³â 10¿ù Global Genes¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î 4¾ï ¸í ÀÌ»óÀÇ »ç¶÷µéÀÌ Èñ±Í À¯Àü ÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ ¼öÄ¡´Â °Ç°­ ÀνĻӸ¸ ¾Æ´Ï¶ó Ä¡·á¹ý°ú ÀÓ»ó ȯ°æÀÇ °³¼±ÀÌ Àý½ÇÈ÷ ÇÊ¿äÇÏ´Ù´Â °ÍÀ» ³ªÅ¸³À´Ï´Ù. ÀǾàǰ °³¹ßÀ» À§Çؼ­´Â ÷´Ü ¿¬±¸¿Í ¾à¹° Ç¥Àû ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ Áö½ÄÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¸¹Àº Áö¿ª¿¡¼­ ÄÚȣƮ ÇÁ·Î±×·¥À» ÅëÇØ ¹ÙÀÌ¿À¹ðÅ©¸¦ °³¹ßÇÏ¿© ¿¬±¸Àڵ鿡°Ô °íǰÁúÀÇ »ùÇÃÀ» Á¦°øÇÔÀ¸·Î½á Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ´õ ³ªÀº ÀÇ·á ÀÎÇÁ¶ó¸¦ ±¸ÃàÇϱâ À§ÇÑ ¿¬±¸ Ȱµ¿¿¡ ´ëÇÑ ÀÌ´Ï¼ÅÆ¼ºê¿Í Á¤ºÎÀÇ °ü½ÉÀº ¿¬±¸¿ë ´Ü¹éÁúÀÇ ÀÀ¿ëÀ» °­È­ÇÏ¿© °á°úÀûÀ¸·Î ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª ´Ü¹éÁú »ý»êÀº ½Ã°£ÀÌ ¸¹ÀÌ ¼Ò¿äµÇ´Â Ȱµ¿À¸·Î, ½Ã¼ú °úÁ¤¿¡¼­ ³ôÀº ¼öÁØÀÇ ÀÛµ¿ Á¶°ÇÀ» À¯ÁöÇØ¾ß ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ ÀçÁ¶ÇÕ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ °è¼Ó Áõ°¡Çϰí ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ±ÔÁ¦ ±â°üÀÇ Áö¿øÀº ¿©ÀüÈ÷ ´À¸° ¼Óµµ·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸¿ë ´Ü¹éÁúÀº ÀϹÝÀûÀ¸·Î ¼÷ÁÖ ¶Ç´Â ¹ßÇö ½Ã½ºÅÛÀ» ÅëÇØ Á¦Á¶µÇ¸ç, ¿©±â¼­ ¿øÇÏ´Â Á¦Ç°¿¡ ƯÁ¤ÇÑ À¯ÀüÀÚ´Â °¨¿°°ú ¹ÚÅ׸®¾Æ ÇüÁú Àüȯ ¶Ç´Â ¹ÙÀÌ·¯½º ÀüÀÌ ´Ü°è¸¦ ÅëÇØ ¹ßÇöµË´Ï´Ù. ÀÌ º¹ÀâÇÑ °úÁ¤Àº Á¾Á¾ Ç¥ÀûÈ­µÇÁö ¾ÊÀº ¿µ¿ªÀÌ °úµµÇÏ°Ô ¹ßÇöµÇ´Â ´ÜÁ¡ÀÌ ÀÖÀ¸¸ç ´õ ¸¹Àº ½Ã°£ÀÌ ¼Ò¿äµÇ±âµµ ÇÕ´Ï´Ù. µû¶ó¼­ ÀçÁ¶ÇÕ ±â¼ú¿¡ ´ëÇÑ ±¸Ã¼ÀûÀÎ °¡À̵å¶óÀΰú ±ÔÁ¤ÀÌ ¾ø´Ù´Â Á¡ÀÌ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀÇ ±Þ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â »çÀÌÅäÄ«ÀÎ ¹× ¼ºÀå ÀÎÀÚ ºÎ¹®Àº 2024³â¿¡ 23.61%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇßÀ¸¸çÀÌ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È 17.62%ÀÇ °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¾à¹° ¹ß°ß ¹× °³¹ßÀ»À§ÇÑ ´Ù¾çÇÑ ÀÓ»ó ¿¬±¸¿¡¼­ ±× ¿ªÇÒ¿¡ ±âÀÎ ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¼÷ÁÖ ¼¼Æ÷º°·Î Æ÷À¯·ù ¼¼Æ÷ ºÎ¹®Àº 2024³â¿¡ 55.73%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. Æ÷À¯·ù ¼¼Æ÷ÀÇ ³ôÀº Á¡À¯À²Àº ÁÖ·Î Àΰ£ ¼¼Æ÷¿Í À¯»çÇÑ »ý¹°ÇÐÀû ±¸¼ºÀ¸·Î ÀÎÇØ ´ÜÀÏ Å¬·Ð Ç×ü, ¹é½Å µîÀ» Æ÷ÇÔÇÑ ¹ÙÀÌ¿À ÀǾàǰ »ý»ê¿¡ µµ¿òÀÌ µÇ±â ¶§¹®ÀÔ´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ ºÎ¹®Àº 2024³â¿¡ 61.48%ÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å¾à ¹ß°ß ¹× °³¹ßÀ» À§ÇÑ ¿¬±¸ Ȱµ¿ÀÇ Áõ°¡¿Í °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿¬±¸¿ë ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â 44.47%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº Á¡À¯À²Àº ÁÖ¿ä ½ÃÀå Ç÷¹À̾î¿Í °­·ÂÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº ¿¹Ãø ±â°£ µ¿¾ÈÀÌ Áö¿ªÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀ» Ȱ¼ºÈ­ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå : Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ½ÃÀå Àü¸Á
  • ºÎ¹® ½º³À¼¦
  • °æÀï ±¸µµÀÇ ½º³À¼¦

Á¦3Àå ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ÇÏÀ§ ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • PESTEL ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå Á¦Ç° ºñÁî´Ï½º ºÐ¼®

  • Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
  • ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°(2018-2030³â)
  • »çÀÌÅä Ä«Àΰú ¼ºÀå ÀÎÀÚ
    • »çÀÌÅäÄ«Àΰú ¼ºÀå ÀÎÀÚ ½ÃÀå(2018-2030³â)
    • ÀÎÅÍÆä·Ð(IFN)
    • ÀÎÅÍ·çŲ(IL)
    • ±âŸ
  • Ç×ü
    • Ç×ü(2018-2030³â)
  • ¸é¿ª üũÆ÷ÀÎÆ® ´Ü¹éÁú
    • ¸é¿ª üũÆ÷ÀÎÆ® ´Ü¹éÁú ½ÃÀå(2018-2030³â)
  • ¹ÙÀÌ·¯½º Ç׿ø
    • ¹ÙÀÌ·¯½º Ç׿ø ½ÃÀå(2018-2030³â)
  • È¿¼Ò
    • È¿¼Ò ½ÃÀå(2018-2030³â)
    • È¿¼Ò
    • ´ë»çÈ¿¼Ò
    • ±âŸ
  • ÀçÁ¶ÇÕ Á¶Àý ´Ü¹éÁú
    • ÀçÁ¶ÇÕ Á¶Àý ´Ü¹éÁú ½ÃÀå(2018-2030³â)
  • È£¸£¸ó
    • È£¸£¸ó ½ÃÀå(2018-2030³â)
  • ±âŸ
    • ±âŸ ½ÃÀå(2018-2030³â)

Á¦5Àå ¼÷ÁÖ ¼¼Æ÷ ºñÁî´Ï½º ºÐ¼®

  • ¼÷ÁÖ ¼¼Æ÷ ºÎ¹® ´ë½Ãº¸µå
  • ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå : ¼÷ÁÖ ¼¼Æ÷ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼÷ÁÖ ¼¼Æ÷º°(2018-2030³â)
  • Æ÷À¯·ù ¼¼Æ÷
    • Æ÷À¯·ù ¼¼Æ÷ ½ÃÀå(2018-2030³â)
  • ¹ÚÅ׸®¾Æ ¼¼Æ÷
    • ¼¼±Õ ¼¼Æ÷ ½ÃÀå(2018-2030³â)
  • È¿¸ð¿Í ±Õ·ù
    • È¿¸ð¿Í ±Õ·ù ½ÃÀå(2018-2030³â)
  • °ïÃæ ¼¼Æ÷
    • °ïÃæ ¼¼Æ÷ ½ÃÀå(2018-2030³â)
  • ±âŸ
    • ±âŸ ½ÃÀå(2018-2030³â)

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷
    • Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ ½ÃÀå(2018-2030³â)
  • Çмú¿¬±¸±â°ü
    • Çмú¿¬±¸±â°ü ½ÃÀå(2018-2030³â)
  • ±âŸ
    • ±âŸ ½ÃÀå(2018-2030³â)

Á¦7Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ª ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå(2018-2030³â)
    • ¿µ±¹
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå(2018-2030³â)
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • ű¹
    • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå(2018-2030³â)
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿¬±¸¿ë ´Ü¹éÁú ½ÃÀå(2018-2030³â)
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ Æ÷Áö¼Å´× ºÐ¼®(2024³â)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ, »óÀå ±â¾÷
    • Thermo Fisher Scientific, Inc.
    • Abcam Plc
    • Miltenyi BIoTec
    • GenScript
    • Bio-Techne
    • Proteintech Group, Inc.
    • ACROBiosystems
    • Sino Biological, Inc.
    • ProSpec-Tany TechnoGene Ltd.
    • New England Biolabs
HBR 25.03.12

Research-grade Proteins Market Growth & Trends:

The global research-grade proteins market size is anticipated to reach USD 1.75 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.49% from 2025 to 2030. The growing investments in research and development within the fields of cancer research and rising demand for personalized medicines are anticipated to contribute to the growth of the market. In addition, the rising government investments in numerous countries for various clinical studies are expected to drive the growth of the market. Moreover, the growing advancements in the biotechnology industry in developing countries are further driving the growth of the market over the forecast period.

The COVID-19 pandemic positively impacted the market due to the surge in research activities for developing vaccines, diagnostics, and therapeutics. As regulatory authorities focused on expediting the approval processes for vaccine candidates, the demand for contract manufacturing increased. Although novel vaccine platforms, such as mRNA vaccines, received significant attention, several recombinant protein vaccine alternatives were also being evaluated. For instance, in July 2022, Novavax, Inc.'s Nuvaxovid (NVX-CoV2373) recombinant protein-based COVID-19 vaccine received an expanded conditional marketing authorization for use in the EU. Furthermore, the pandemic highlighted the need for agile and flexible manufacturing abilities in biologics. This factor is expected to boost the competitive landscape and fuel market growth in the near future.

As per Global Genes, in October 2019, more than 400 million people globally are living with rare and genetic diseases. This figure indicates the dire need for treatments and the betterment of clinical settings as well as health awareness. The need for advanced research and drug targeting mechanisms knowledge is crucial for medicine development. Many regions have developed biobanks from cohort programs to provide researchers with high-quality samples for revolutionizing treatment efforts. This is expected to result in an increased focus on biomarkers discovery for various conditions. Thus, initiatives and government interest in research activities for building a better healthcare infrastructure are expected to enhance the applications of research-grade proteins, consequently driving market growth.

However, protein production is a time-consuming activity, which often requires high maintenance of the operating conditions during the procedure. Even with the high and ever-increasing demand for these recombinant products, support from regulatory bodies is still evolving at a slower pace. Research-grade proteins are usually manufactured via a host or an expression system, where the gene specific to the desired product is expressed through stages of transfection and bacterial transformation or viral transduction. This complex process often has the disadvantage of over-expression of untargeted regions and even utilizes more time. Thus, the absence of specific guidelines and regulations for recombinant technology is a major factor hindering the booming market of research-grade proteins.

Research-grade Proteins Market Report Highlights:

  • Based on product, the cytokines & growth factors segment dominated the market with the largest revenue share of 23.61% in 2024 and the segment is anticipated to grow with the fastest CAGR of 17.62% over the forecast period. This can be attributed to its role in various clinical studies for drug discovery and development
  • Based on host cell, the mammalian cells segment dominated the market with the largest revenue share of 55.73% in 2024. The large share is primarily due to its similar biological makeup to human cells, which helps in the production of biopharmaceuticals, including monoclonal antibodies, vaccines, and many more
  • Based on end-use, the pharmaceutical & biotechnology companies segment held the largest market share of 61.48% in 2024. Due to the increasing number of research activities for drug discoveries & development and the growing demand for personalized medicines, the demand for research-grade proteins is projected to boost over the forecast period
  • Based on region, North America dominated the market with a revenue share of 44.47% in 2024. This large share is attributed to the presence of major market players and robust healthcare infrastructure. These factors are anticipated to boost the market for research-grade proteins in the region over the forecast period

Table of Contents

Chapter 1. Research-grade Proteins Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Host Cell Segment
    • 1.2.3. End Use Segment
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives

Chapter 2. Research-grade Proteins Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Research-grade Proteins Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing use of recombinant proteins in research activities
      • 3.3.1.2. Growing research activities for drug discovery and precision medicine
      • 3.3.1.3. Rising adoption of biologics & biosimilars
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Regulatory and safety concerns regarding protein production
      • 3.3.2.2. Dearth of skilled personnel and expertise
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTEL Analysis
    • 3.4.2. Porter's Five Forces Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Research-grade Proteins Market: Product Movement Analysis
  • 4.3. Global Research-Grade Proteins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Cytokines & Growth Factors
    • 4.4.1. Cytokines & Growth Factors Market, 2018 - 2030 (USD Million)
    • 4.4.2. Interferons (IFNs)
      • 4.4.2.1. Interferons (IFNs) Market, 2018 - 2030 (USD Million)
    • 4.4.3. Interleukins (ILs)
      • 4.4.3.1. Interleukins (ILs) Market, 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.5. Antibodies
    • 4.5.1. Antibodies, 2018 - 2030 (USD Million)
  • 4.6. Immune Checkpoint Proteins
    • 4.6.1. Immune Checkpoint Proteins Market, 2018 - 2030 (USD Million)
  • 4.7. Virus Antigens
    • 4.7.1. Virus Antigens Market, 2018 - 2030 (USD Million)
  • 4.8. Enzymes
    • 4.8.1. Enzymes Market, 2018 - 2030 (USD Million)
    • 4.8.2. Kinases
      • 4.8.2.1. Kinases Market, 2018 - 2030 (USD Million)
    • 4.8.3. Metabolic Enzymes
      • 4.8.3.1. Metabolic Enzymes Market, 2018 - 2030 (USD Million)
    • 4.8.4. Others
      • 4.8.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.9. Recombinant Regulatory Proteins
    • 4.9.1. Recombinant Regulatory Proteins Market, 2018 - 2030 (USD Million)
  • 4.10. Hormones
    • 4.10.1. Hormones Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Host Cell Business Analysis

  • 5.1. Host Cell Segment Dashboard
  • 5.2. Research-grade Proteins Market: Host Cell Movement Analysis
  • 5.3. Global Research-Grade Proteins Market Size & Trend Analysis, by Host Cell, 2018 to 2030 (USD Million)
  • 5.4. Mammalian Cells
    • 5.4.1. Mammalian Cells Market, 2018 - 2030 (USD Million)
  • 5.5. Bacterial Cells
    • 5.5.1. Bacterial Cells Market, 2018 - 2030 (USD Million)
  • 5.6. Yeast & Fungi
    • 5.6.1. Yeast & Fungi Market, 2018 - 2030 (USD Million)
  • 5.7. Insect Cells
    • 5.7.1. Insect Cells Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Research-grade Proteins Market: End Use Movement Analysis
  • 6.3. Global Research-Grade Proteins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. U.S. Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Canada Research-grade Proteins Market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. UK Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Germany Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.4. Spain
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Spain Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.5. France
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. France Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.6. Italy
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Italy Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Denmark Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Sweden Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Norway Research-grade Proteins Market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia-Pacific Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Japan Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. China Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. India Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. South Korea Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Thailand Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.5.7. Australia
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Australia Research-grade Proteins Market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Brazil Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Argentina Research-grade Proteins Market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. South Africa Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Saudi Arabia Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. UAE Research-grade Proteins Market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Kuwait Research-grade Proteins Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific, Inc.
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Abcam Plc
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Miltenyi Biotec
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Product Benchmarking
      • 8.4.3.3. Strategic Initiatives
    • 8.4.4. GenScript
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Bio-Techne
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Proteintech Group, Inc.
      • 8.4.6.1. Company Overview
      • 8.4.6.2. Product Benchmarking
      • 8.4.6.3. Strategic Initiatives
    • 8.4.7. ACROBiosystems
      • 8.4.7.1. Company Overview
      • 8.4.7.2. Product Benchmarking
      • 8.4.7.3. Strategic Initiatives
    • 8.4.8. Sino Biological, Inc.
      • 8.4.8.1. Company Overview
      • 8.4.8.2. Product Benchmarking
      • 8.4.8.3. Strategic Initiatives
    • 8.4.9. ProSpec-Tany TechnoGene Ltd.
      • 8.4.9.1. Company Overview
      • 8.4.9.2. Product Benchmarking
      • 8.4.9.3. Strategic Initiatives
    • 8.4.10. New England Biolabs
      • 8.4.10.1. Company Overview
      • 8.4.10.2. Product Benchmarking
      • 8.4.10.3. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦